×
About 759 results

ALLMedicine Chemical Burns Center

Research & Reviews  353 results

Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Bo...
https://doi.org/10.1007/s12325-020-01381-3
Advances in Therapy; Zhang Y, Ou Z et. al.

May 19th, 2020 - This study aimed to describe the clinical features, surgical management of the eyelid and ocular surface, and outcomes of 16 patients implanted with a Boston type I keratoprosthesis (KPro). A retrospective, single-center, consecutive case series o...

Polymodal Sensory Transduction in Mouse Corneal Epithelial Cells.
https://doi.org/10.1167/iovs.61.4.2
Investigative Ophthalmology & Visual Science; Lapajne L, Lakk M et. al.

Apr 9th, 2020 - Contact lenses, osmotic stressors, and chemical burns may trigger severe discomfort and vision loss by damaging the cornea, but the signaling mechanisms used by corneal epithelial cells (CECs) to sense extrinsic stressors are not well understood. ...

Enzymatic debridement as an effective treatment for combined flame and chemical burns c...
https://doi.org/10.1016/j.ajem.2020.02.030
The American Journal of Emergency Medicine; Claes KEY, Vyncke T et. al.

Feb 18th, 2020 - Since its introduction on the market in 2007, the number of reports on injuries caused by the ignition or explosion of electronic nicotine delivery systems (ENDS) has increased significantly. Two male patients have been treated at our burn center,...

Long-term visual outcomes of the Boston type I keratoprosthesis in Canada.
https://doi.org/10.1136/bjophthalmol-2019-315345
The British Journal of Ophthalmology; Szigiato AA, Bostan C et. al.

Feb 16th, 2020 - To evaluate long-term visual outcomes of Boston type I keratoprosthesis (KPro) surgery and identify risk factors for visual failure. Single surgeon retrospective cohort study including 85 eyes of 74 patients who underwent KPro implantation to trea...

Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe ...
https://doi.org/10.1097/ICO.0000000000002272
Cornea Huang ST, Zhou T et. al.

Feb 10th, 2020 - To investigate whether subconjunctival bevacizumab help prevent corneal graft neovascularization and prolong the graft survival of patients with chemical burns. We performed a prospective nonrandomized comparative case series study. Twenty-six eye...

see more →

Clinicaltrials.gov  379 results

Treatment of Oculoplastic and Ocular Surface Disease in Eyes Implanted with a Type I Bo...
https://doi.org/10.1007/s12325-020-01381-3
Advances in Therapy; Zhang Y, Ou Z et. al.

May 19th, 2020 - This study aimed to describe the clinical features, surgical management of the eyelid and ocular surface, and outcomes of 16 patients implanted with a Boston type I keratoprosthesis (KPro). A retrospective, single-center, consecutive case series o...

Polymodal Sensory Transduction in Mouse Corneal Epithelial Cells.
https://doi.org/10.1167/iovs.61.4.2
Investigative Ophthalmology & Visual Science; Lapajne L, Lakk M et. al.

Apr 9th, 2020 - Contact lenses, osmotic stressors, and chemical burns may trigger severe discomfort and vision loss by damaging the cornea, but the signaling mechanisms used by corneal epithelial cells (CECs) to sense extrinsic stressors are not well understood. ...

Enzymatic debridement as an effective treatment for combined flame and chemical burns c...
https://doi.org/10.1016/j.ajem.2020.02.030
The American Journal of Emergency Medicine; Claes KEY, Vyncke T et. al.

Feb 18th, 2020 - Since its introduction on the market in 2007, the number of reports on injuries caused by the ignition or explosion of electronic nicotine delivery systems (ENDS) has increased significantly. Two male patients have been treated at our burn center,...

Long-term visual outcomes of the Boston type I keratoprosthesis in Canada.
https://doi.org/10.1136/bjophthalmol-2019-315345
The British Journal of Ophthalmology; Szigiato AA, Bostan C et. al.

Feb 16th, 2020 - To evaluate long-term visual outcomes of Boston type I keratoprosthesis (KPro) surgery and identify risk factors for visual failure. Single surgeon retrospective cohort study including 85 eyes of 74 patients who underwent KPro implantation to trea...

Early Application of Bevacizumab After Sclerocorneal Grafting for Patients With Severe ...
https://doi.org/10.1097/ICO.0000000000002272
Cornea Huang ST, Zhou T et. al.

Feb 10th, 2020 - To investigate whether subconjunctival bevacizumab help prevent corneal graft neovascularization and prolong the graft survival of patients with chemical burns. We performed a prospective nonrandomized comparative case series study. Twenty-six eye...

see more →

News  27 results

'Chemical Burns' Seen as Possible Cause of Vaping Lung Damage
https://www.medscape.com/viewarticle/919361

Oct 2nd, 2019 - Lung injuries from vaping probably result from direct toxicity or tissue damage caused by noxious chemical fumes, rather than from an accumulation of lipids in the lungs, pathology data suggest. "We were not surprised by what we found, regarding t...

Beauty Products Send One Young Child to the ED Every Two Hours
https://www.medscape.com/viewarticle/914677

Jun 22nd, 2019 - (Reuters Health) - Injuries from cosmetics, shampoo and other personal care products send one young child to an emergency department in the United States every two hours, according to a new study. The researchers estimated that nearly 65,000 child...

Ocular Chemical Burns in the Dermatology Office: A Practical Approach to Managing Safety Precautions
https://www.mdedge.com/dermatology/article/202365/aesthetic-dermatology/ocular-chemical-burns-dermatology-office-practical/page/0/1?channel=177

Jun 5th, 2019 - Symptoms of Ocular Chemical Exposure Signs and symptoms associated with ocular chemical exposures include erythema, pain, tearing, photosensitivity, eyelid swelling, foreign body sensation, changes in vision, and corneal clouding. 3,5,9,28 Specifi.

Europe approves Western world's first stem-cell therapy for rare eye condition
https://www.reuters.com/article/us-health-stemcells-europe/europe-approves-western-worlds-first-stem-cell-therapy-for-rare-eye-condition-idUSKBN0LO18X20150220

Feb 20th, 2015 - (Reuters) - Europe has approved the Western world’s first medicine containing stem cells to treat a rare condition caused by burns to the eye, marking a milestone in the use of the technology. Holoclar, from privately held Italian company Chiesi, ...

see more →